Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Cancer 8, 573 (1 August 2008) | doi:10.1038/nrc2456
Targeting thyroid angiogenesis
Abstract
Promising results from two phase II trials that assess the use of the anti-angiogenesis drugs sorafenib and axitinib in patients with advanced thyroid cancer were published recently in the Journal of Clinical Oncology. Patients with thyroid cancer are usually treated with radioactive iodine (131I) or surgery, but those patients for whom these strategies are not appropriate or successful have limited treatment options.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
